BACKGROUND

The Evi-1 proto-oncogene contains two zinc finger domains, the second of which is essential for transactivation of the c-Fos promoter and for AP-1 activation. The first zinc finger domain binds to Smad3, suppressing its activity and inhibiting TGFβ signaling. The t(3;21)(q26;q22) chromosomal translocation produces a chimeric transcription factor, AML-1/Evi-1, that appears to suppress the transactivation of AML-1, which is a stimulator of myeloid cell differentiation. Inappropriate Evi-1 gene expression in hematopoietic cells has been shown to be associated with acute myelogenous leukemia (AML) and myelodysplastic syndromes.

REFERENCES


CHROMOSOMAL LOCATION

Genetic locus: MECOM (human) mapping to 3q26.2.

SOURCE

Evi-1 (2331C1a1) is a mouse monoclonal antibody raised against a recombinant protein corresponding to an internal region of Evi-1 of human origin.

PRODUCT

Each vial contains 100 µg IgG1 in 1.0 ml PBS with < 0.1% sodium azide and 1.0% BSA.

APPLICATIONS

Evi-1 (2331C1a1) is recommended for detection of Evi-1 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and immunoprecipitation (1-2 µg per 100-500 µg of total protein [1 ml of cell lysate]).

Suitable for use as control antibody for Evi-1 siRNA (h): sc-37873, Evi-1 shRNA Plasmid (h): sc-37873-SH and Evi-1 shRNA (h) Lentiviral Particles: sc-37873-V.

Molecular Weight of Evi-1: 145 kDa.

Positive Controls: Evi-1 (h): 293T Lysate: sc-177200, CCRF-CEM cell lysate: sc-2225 or Hep G2 cell lysate: sc-2227.

DATA

STOREAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our website at www.scbt.com for detailed protocols and support products.